Preclinical and clinical study on [¹⁸F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer's disease.

ABSTRACT:

Background

The deposition of β-amyloid (Aβ) in the brain is a biomarker of Alzheimer's disease (AD). Highly sensitive Aβ positron emission tomography (PET) imaging plays an essential role in diagnosing and evaluating the therapeutic effects of AD.

Aim

To synthesize a new Aβ tracer [¹⁸F]DRKXH1 (5-(4-(6-(2-[18]fluoroethoxy)ethoxy)imidazo[1,2-alpha]pyridin-2-yl)phenyl) and evaluate the tracer performance by biodistribution analysis, in vivo small-animal PET-CT dynamic scan, ex vivo and in vitro autoradiography, and PET in human subjects.

Methods

[¹⁸F]DRKXH1 was synthesized automatically by the GE FN module. Log D (pH 7.4) and biodistribution of [¹⁸F]DRKXH1 were investigated. Small-animal-PET was used for [¹⁸F]DRKXH1 and [¹

SUBMITTER: Xu M 

PROVIDER: S-EPMC8803783 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature